Dr. Reddy’s Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander. The launch was approved by the US Food and Drug Administration (USFDA).<\/p>\n
According to Milan Kalawadia, CEO of North America Generics at Dr. Reddy’s Laboratories, the launch is a significant addition to the company’s existing portfolio in the OTC eye-care space. The company already offers Olopatadine Hydrochloride Ophthalmic Solution, and this new launch further expands its presence in the market. Kalawadia also highlighted the company’s capabilities in bringing store-brand equivalents of OTC brands to the US market, citing the first-to-market launch as a testament to these capabilities.<\/p>\n
The Pataday brand, which Dr. Reddy’s solution is equivalent to, had significant sales in the US market, with approximately $69.9 million in sales over the 52-week period ending December 27, 2025. This indicates a substantial market demand for the product, and Dr. Reddy’s launch is likely to capitalize on this demand.<\/p>\n
The launch of Olopatadine Hydrochloride Ophthalmic Solution is a strategic move by Dr. Reddy’s to expand its presence in the US OTC market. The company’s ability to bring generic equivalents of popular brands to the market can help increase accessibility and affordability of these products for consumers. With its strong portfolio in the OTC eye-care space, Dr. Reddy’s is well-positioned to compete in the market and provide consumers with high-quality, affordable options for their eye care needs.<\/p>\n
Overall, the launch of Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution is a significant development in the US OTC market, and the company’s capabilities in bringing generic equivalents to the market are likely to have a positive impact on consumers and the industry as a whole.<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Reddy’s Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander. The launch was approved by […]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89802","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89802,"position":0},"title":"Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89802,"position":1},"title":"Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89737,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/02\/usfda-deals-a-blow-to-dr-reddys-biosimilar-denosumab-avt03-following-an-inspection-of-the-manufacturing-facility\/","url_meta":{"origin":89802,"position":2},"title":"USFDA deals a blow to Dr Reddy’s biosimilar denosumab AVT03 following an inspection of the manufacturing facility.","author":"Team Small News","date":"January 2, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has faced a setback in its efforts to bring its denosumab biosimilar, AVT03, to the US market. The US Food and Drug Administration (USFDA) has issued a warning letter to the company after conducting an inspection of its manufacturing facility. The inspection revealed several issues with the\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89727,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/31\/gurupyar-reddy-production-complex-injections-head-at-dr-reddys-laboratories\/","url_meta":{"origin":89802,"position":3},"title":"Gurupyar Reddy, Production Complex Injections Head at Dr Reddy’s Laboratories","author":"Team Small News","date":"December 31, 2025","format":false,"excerpt":"The Vizag Pharma Summit 2025 is scheduled to take place on December 17th, 2025, at the Fairfield by Marriott in Vizag. The event will feature a speaker, Mr. Gurupyar Reddy, who is the Head of Production Complex Injections at Dr. Reddy's Laboratories. Mr. Reddy will be discussing the topic of\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89763,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/dr-reddys-introduces-hevaxin-indias-inaugural-hepatitis-e-vaccine-approved-by-the-dcgi-specifically-designed-for-adult-use\/","url_meta":{"origin":89802,"position":4},"title":"Dr. Reddy’s introduces Hevaxin, India’s inaugural Hepatitis E vaccine approved by the DCGI, specifically designed for adult use.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV infection in adults aged 18 to 65 years. Clinical\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89831,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/21\/dr-reddys-and-eternal-gain-attention-as-kpi-green-witnesses-significant-uptick\/","url_meta":{"origin":89802,"position":5},"title":"Dr Reddy’s and Eternal Gain Attention as KPI Green Witnesses Significant Uptick","author":"Team Small News","date":"January 21, 2026","format":false,"excerpt":"KPI Green Energy Ltd. has reported impressive financial results for the third quarter, with a 39.4% year-over-year increase in net profit to \u20b9118 crore. The company's revenue also saw a significant rise of 44.6% to \u20b9663 crore during the quarter. Additionally, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89802"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89802\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}